DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Thoraxonkologie » Nicht-kleinzelliges Lungenkarzinom

Alle Linien

AIO-YMO/TRK-0120
Phase II Studie zu Osimertinib und Strahlentherapie bei EGFR+, fortgeschrittenem nichtkleinzelligem Lungenkrebs (Aktiv)

CPDR001X2X01B
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (Aktiv)

MAGELLAN
Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location (Aktiv)

METalmark
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (Aktiv)

MK-3475-587
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)

NVL-520-01
Phase-1/2-Studie zu NVL-520 bei Patienten mit fortgeschrittenem NSCLC und anderen soliden Tumoren (Aktiv)

Rezilient 2
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations. (Aktiv)

SenPET
Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)

Trident-1
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Aktiv)

UC02-PSMA-01
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (Aktiv)

Erstlinie

B-FAST
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: blood-first assay screening trial) (Aktiv)

BI 1479-0008 (Phase III)
Phase-3-Studie zu BI 1810631 bei Patienten mit fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkrebs mit HER2-Mutationen (Aktiv)

BO42777
A Phase I-III, Multicenter Study Evaluating The Efficacy And Safety Of Multiple Therapies In Cohorts Of Patients Selected According To Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (Aktiv)

CACZ885T2301
Study of efficacy and safety of canakinumab as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected non-small cell lung cancer (Aktiv)

COCOON
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib (Aktiv)

CRISP
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (Aktiv)

CodeBreaK 202
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (Aktiv)

DESTINY-Lung04
Eine offene, randomisierte, multizentrische Phase-III-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Trastuzumab Deruxtecan (T-DXd) im Vergleich zu Chemotherapie plus Pembrolizumab für die Erstlinienbehandlung von fortgeschrittenem/metastasiertem nicht-squamösem nicht-kleinzelligem Lungenkrebs mit HER2 Exon 19 oder 20 Mutation (Aktiv)

DURATION
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (Aktiv)

DZ2022E0005
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation (Aktiv)

ESPADURVA
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) (Aktiv)

GO41717
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (Aktiv)

GSK-213824
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer (Aktiv)

KEYVIBE-006
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC  (Aktiv)

Keynote867
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) (Aktiv)

KontRASt-06
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. (Aktiv)

LCNEC-ALPINE
A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)

LIBRETTO-432 (J2G-MC-JZJX)
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (Aktiv)

Lung Adaura 2
Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (Aktiv)

MK-7339-012
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (Aktiv)

MK-7684A-003
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003) (Aktiv)

NEOpredict (CA224-063)
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (Aktiv)

NEOpredict-EGFR
Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harboring oncogenic EGFR mutations (Aktiv)

Neo-ADAURA
A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Factor Receptor mutation positive resectable Non-Small Cell Lung Cancer (Aktiv)

NeoTRACK
Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing: a Non-randomized, Open-label, Single-arm Phase II Study (Aktiv)

PACE-LUNG
Phase II Studie zu zusätzlicher Chemotherapie bei EGFR-positivem nicht-kleinzelligem Lungenkrebs (Aktiv)

PACIFIC-8
Eine globale Studie zur Bewertung der Auswirkungen von Durvalumab + Domvanalimab nach gleichzeitiger Radiochemotherapie bei Teilnehmern mit inoperablem nicht-kleinzelligem Lungenkrebs im Stadium III (PACIFIC 8) (Aktiv)

PALOMA-2
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in multiple regimens in patients with Advanced or Metastatic Solid Tumors including EGFR mutated NSCLC (PALOMA-2) (Aktiv)

PRONTOX
Protonenbehandlung zur primären Radiochemotherapie bei fortgeschrittenen Nicht-kleinzelligen Bronchialkarzinomen (Aktiv)

RAZOR
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer (Aktiv)

Roche Horizon 1(BO42777)
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (Aktiv)

Roche LAG3 (BO44178)
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Aktiv)

STAR-121
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (Aktiv)

TRADE-hypo
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (Aktiv)

TRIDENT-3
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naive ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (Aktiv)

TROPION-Lung08
A randomized open-label phase 3 trial of Dato-DXd plus Pembrolizumab vs Pembrolizumab alone in treatment naïve subjects with advanced or metastatic PD-L1 High (TPS>= 50%) NSCLC without actionable genomic alterations (Tropion-LUNG08) (Aktiv)

TroFuse-007
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (Aktiv)

Tropion-Lung07
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (Aktiv)

eVOLVE-Lung02 (D798AC00001)
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC). (Aktiv)

Zweitlinie oder später

AbbVieM18-868
Eine offene, randomisierte, kontrollierte, globale Phase-3-Studie mit Telisotuzumab Vendotin (ABBV-399) im Vergleich zu Docetaxel bei Patienten mit zuvor behandeltem c-Met-überexprimierendem EGFR-Wildtyp, lokal fortgeschrittenem/metastasiertem, nicht-squamösem nicht-kleinzelligem Lungenkrebs. (Aktiv)

Achilles ATX-NS-001
An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer (Aktiv)

Antelope
Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma (Aktiv)

BI 1403-0011 - BRIGHTLINE-2
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (Aktiv)

BI 1479-0001
An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations (Aktiv)

BNT116-01 LuCa-MERIT-1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (Aktiv)

Be6A LUNG-01(SGNB6A-002)
A Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A Compared With Docetaxel in Adult Subjects With Previously Treated Non-small Cell Lung Cancer (Aktiv)

BoB Module 1
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)

CA022-001
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors (Aktiv)

CHRYSALIS
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (Aktiv)

CMGY825A12101
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (Aktiv)

Chrysalis-2
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Aktiv)

D533BC00001
A Phase III, Open-Label, Randomised, Multicentre Study Of Ceralasertib Plus Durvalumab Versus Docetaxel In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, And Whose Disease Has Progressed On Or After Prior Anti-PD-(L)1 Therapy And Platinum-Based Chemotherapy: LATIFY (Aktiv)

DURATION
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (Aktiv)

GSK ICOS
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants (Aktiv)

Herthena-Lung01
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC (Aktiv)

Krascendo 1
A Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Divarasib versus Sotorasib or Adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic non-small cell lung cancer. (Aktiv)

L-AP-IS Lunge
L-AP-IS: Lung cancer, Ablative high Precision radiotherapy and the Immune System: Evaluation of the immune-modulatory effects of stereotactic body radiation therapy (SBRT) of pulmonary lesions (Aktiv)

LIBRETTO-001
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)

LOXO-TRK-15003
A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101 (Aktiv)

M22-142
Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment (Aktiv)

MARIPOSA-2
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (Aktiv)

MCLA-128-CL01/MERUS
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)

MK-2870-004
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (Aktiv)

Novartis CDKY709A12101C
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC (Aktiv)

Novartis CFKA115A12101
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers (Aktiv)

Pacific-9
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) D9078C00001 (Aktiv)

RadImmun-NSCLC
Evaluierung von systemischen Effekten der kombinierten palliativen Strahlen- und Immuntherapie bei nicht kleinzelligem Bronchialkarzinom nach unzureichendem Ansprechen auf Immun-Checkpoint-Inhibitoren (Aktiv)

SORATRAM
Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

Sanofi CARMEN
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (Aktiv)

VALO-001
Phase I Studie zu einer Erstlinientherapie bei Nicht-Kleinzelligem Lungenkarzinom, Schwarzem Hautkrebs oder Brustkrebs (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de